ICON Public Company (ICLR:NASDAQ) Investor Relations Material

Overview

Dublin-based clinical research organization ICON Public Limited Company is a leading provider of outsourced development and commercialization services across the globe. The company specializes in the strategic management and analysis of programs supporting various phases of the clinical development process, from compound selection to Phase I-IV clinical studies. Their services include clinical development services, clinical research services, and laboratory services. The company also offers commercial positioning, early phase, language, medical imaging, and strategic solutions, as well as clinical trial management, consulting, and contract staffing services. ICON Public Limited Company caters to a wide range of industries, including pharmaceutical, biotechnology, and medical device, as well as government and public health organizations. Since its incorporation in 1990, the company has expanded its operations to Ireland, the rest of Europe, the United States, and beyond. With a robust suite of services designed to meet clients' specific needs, ICON remains a key player in the clinical research landscape.

Frequently Asked Questions

What is ICON Public Company's ticker?

ICON Public Company's ticker is ICLR

What exchange is ICON Public Company traded on?

The company's shares trade on the NASDAQ stock exchange

Where are ICON Public Company's headquarters?

They are based in Dublin, Ireland

How many employees does ICON Public Company have?

There are 10,000+ employees working at ICON Public Company

What is ICON Public Company's website?

It is iconplc.com

What type of sector is ICON Public Company?

ICON Public Company is in the Healthcare sector

What type of industry is ICON Public Company?

ICON Public Company is in the Biotechnology industry

Who are ICON Public Company's peers and competitors?

The following five companies are ICON Public Company's industry peers:

- 89Bio

- Stealth BioTherapeutics Corp.

- Proteomics International

- Cidara Therapeutics Inc

- XOMA Ltd.